Clovis Oncology, Inc.

Practice Area: 
Stock Symbol: 
Case Status: 
Class Period: 
October 26, 2015 to November 16, 2015

We are investigating possible securities fraud claims against Clovis resulting from inaccurate statements Clovis made regarding its financial performance.

Our investigation focuses on the extent to which Clovis issued false and misleading statements regarding its past and future business performance and prospects.  Specifically, the investigation is related to Clovis’ disclosure that its lead drug candidate rociletinib is less effective than previously presented, resulting in the delay of regulatory approval of its drug because the FDA has asked for more data. Clovis also admitted that it knew of this lower effectiveness since the end of October.